2023-07-11 15:02:45 ET
Israeli drug developer Purple Biotech ( NASDAQ: PPBT ) reported encouraging Phase 1 data for its immuno-oncology therapy CM24 in the treatment of advanced pancreatic cancer, with initial results from a Phase 2 study expected by the end of 2023.
Purple said that the overall survival rate for patients taking CM24 in combination with nivolumab was comparable to what has been observed for patients treated with chemotherapy, with the median rate in the range of three to four months. It added that based on the data, the recommended dose was the highest administered, 20mg/kg.
The Phase 1 trial tested CM24 in combination with nivolumab in patients with advanced pancreatic ductal adenocarcinoma who had already been treated with two other therapies. Purple is testing the drug combination as part of a collaboration with Bristol Myers Squibb ( BMY ), which markets nivolumab under the brand name Opdivo.
Purple said initial results from a Phase 2 study evaluating CM24 in combination with nivolumab and chemotherapy versus chemotherapy alone are expected by the end of the year, with topline data anticipated in 2024.
Shares of Purple were down 9% in afternoon trading Tuesday.
More on Purple:
Purple Biotech GAAP EPS of -$0.25 beats by $0.12
Purple Biotech CEO Gil Efron takes medical leave, Isaac Israel named acting CEO
Purple Biotech rises 10% on acquisition of cancer therapy developer Immunorizon
For further details see:
Israel's Purple reports encouraging early data for pancreatic cancer drug